FDA ReviewedUpdated May 29, 2026

Contrave Guide

Contrave is a fixed-dose oral combination of naltrexone HCl 8 mg (an opioid receptor antagonist) and bupropion HCl 90 mg (a dopamine and norepinephrine reuptake inhibitor) formulated as an extended-release tablet for chronic weight management. It was FDA-approved September 10, 2014 and is currently marketed by Currax Pharmaceuticals (the U.S. SPL labeler of record is Nalpropion Pharmaceuticals LLC, a Currax subsidiary). Contrave is not a GLP-1 receptor agonist — it acts in the brain on appetite-regulating hypothalamic neurons and on the mesolimbic dopamine reward circuit. Average weight loss in the pivotal COR trials at the 32 mg / 360 mg daily maintenance dose was roughly 4-5% body weight at 56 weeks placebo-subtracted, substantially less than GLP-1s like Wegovy (~14.9%) or Zepbound (~22.5%), positioning Contrave as a lower-cost option for patients who cannot tolerate GLP-1 gastrointestinal side effects or who have co-occurring nicotine or alcohol use disorder where bupropion or naltrexone may offer secondary benefit.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed

At a Glance

Generic NameNaltrexone hydrochloride / Bupropion hydrochloride
Brand NamesContrave
FDA StatusFDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (September 10, 2014). Originally developed by Orexigen Therapeutics; Orexigen filed Chapter 11 in 2018 and the Contrave assets were acquired by Nalpropion Pharmaceuticals (a joint venture of Pernix Therapeutics and a Highbridge-led investor group). Nalpropion was subsequently rolled up into Currax Pharmaceuticals, which now markets Contrave in the United States. Not FDA-approved for pediatric use.[1]
Approval DateSeptember 10, 2014[1]

How Contrave Works

Bupropion stimulates hypothalamic pro-opiomelanocortin (POMC) neurons, which release alpha-MSH to reduce appetite, but POMC neurons also release beta-endorphin, which feeds back onto mu-opioid receptors on the POMC neurons themselves and shuts them off — limiting the appetite-suppressing effect. Naltrexone, by blocking those mu-opioid receptors, disables that auto-inhibitory feedback loop and allows bupropion's POMC activation to persist longer and more strongly. The two agents together also modulate the mesolimbic dopamine reward circuit (ventral tegmental area to nucleus accumbens), which is thought to reduce food cravings and the hedonic drive to eat palatable foods.[2]

Dosing Schedule

Contrave uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Week 11 tablet (8 mg naltrexone / 90 mg bupropion) in the morning; no evening dose
Week 21 tablet in the morning and 1 tablet in the evening (16 mg / 180 mg total daily)
Week 32 tablets in the morning and 1 tablet in the evening (24 mg / 270 mg total daily)
Week 4 onward2 tablets in the morning and 2 tablets in the evening — maintenance dose 32 mg naltrexone / 360 mg bupropion total daily

Side Effects

Common (≥5% and ≥1.5× placebo in pooled phase 3 trials): nausea (~32%), constipation (~19%), headache (~17%), vomiting (~10%), dizziness (~10%), insomnia (~9%), dry mouth (~8%), diarrhea (~7%). Serious (rare): seizures (risk increases at doses above 32/360 mg daily or with high-fat meals, which raise systemic exposure), increased blood pressure and heart rate (most pronounced in the first three months), hepatotoxicity, angle-closure glaucoma, severe allergic reactions, hyponatremia/SIADH, activation of mania in bipolar patients. Boxed warning: suicidal thoughts and behaviors — bupropion is a member of the antidepressant class and carries the class-wide boxed warning for increased risk of suicidal ideation in children, adolescents, and young adults; monitor all patients for emergence or worsening of depression and suicidality, especially during initiation and dose changes. Contraindicated in patients with uncontrolled hypertension, seizure disorders, anorexia or bulimia, chronic opioid use (naltrexone will precipitate withdrawal), abrupt discontinuation of alcohol or benzodiazepines, current or recent (within 14 days) MAOI use, or pregnancy.[1][2]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

Contrave's FDA approval was supported by four pivotal 56-week phase 3 trials in the Contrave Obesity Research (COR) program. COR-I (Greenway FL et al., Lancet 2010, PMID 20673995; N=1,742 adults with BMI 30-45, or BMI 27-45 with dyslipidemia or hypertension) showed mean weight loss of 6.1% with naltrexone SR 32 mg / bupropion SR 360 mg versus 1.3% with placebo, and 48% of patients on the maintenance dose lost ≥5% body weight vs 16% on placebo. COR-II (Apovian CM et al., Obesity 2013, PMID 23408728; N=1,496) confirmed the COR-I efficacy in a second randomized trial of the 32/360 mg dose, with mean weight loss of 6.4% versus 1.2% placebo and 50.5% achieving ≥5% loss versus 17.1%. COR-Diabetes (Hollander P et al., Diabetes Care 2013, PMID 24144653; N=505 adults with type 2 diabetes) showed 5.0% weight loss vs 1.8% placebo plus a 0.6 percentage-point greater HbA1c reduction at 56 weeks. COR-BMOD (Wadden TA et al., Obesity 2011, PMID 20559296; N=793) tested Contrave layered onto an intensive behavior-modification program and produced 9.3% weight loss vs 5.1% with placebo plus behavior modification — the largest absolute weight-loss effect in the COR program, attributable to the added behavioral arm. Across all four trials, placebo-subtracted weight loss was approximately 4-5% body weight, substantially below the 11-15% placebo-subtracted weight loss seen in modern GLP-1 trials (STEP-1, SURMOUNT-1).[2]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Contrave

These telehealth providers offer access to naltrexone hydrochloride / bupropion hydrochloride or compounded equivalents with online consultations and home delivery.

9.0/ 10

CoreAge Rx

Best for: best overall value

★★★★4.5

Editorial score · methodology

$149/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full CoreAge Rx review →
9.0/ 10

TrimRx

Best for: best overall value

★★★★4.5

Editorial score · methodology

$199/mo
CompoundedSemaglutide
Get StartedRead full TrimRx review →
8.7/ 10

Amazon One Medical

Best for: the most authoritative branded GLP-1 channel with same-day delivery and integrated manufacturer savings

★★★★4.4

Editorial score · methodology

$25/mo
BrandOrforglipron
Get StartedRead full Amazon One Medical review →
8.7/ 10

NovoCare Pharmacy

Best for: branded Wegovy at the lowest manufacturer-direct self-pay price

★★★★4.4

Editorial score · methodology

$199/mo
BrandSemaglutide
Get StartedRead full NovoCare Pharmacy review →
8.7/ 10

Vytora Health

Best for: Patients seeking month-to-month or 3-month-bundle compounded semaglutide or tirzepatide with the option of brand-name Mounjaro/Zepbound on a single LegitScript-approved + HIPAA-compliant platform with named pharmacy partners and transparent operating-PC disclosure. Particularly suited for patients in KS, LA, MS, NM, WV where Vytora's audio-visit option satisfies state telehealth compliance.

★★★★4.4

Editorial score · methodology

$150/mo
CompoundedSemaglutideTirzepatideMounjaroZepbound
Get StartedRead full Vytora Health review →
8.6/ 10

Enhance MD

Best for: lab-monitored compounded GLP-1 with mandatory video visit

★★★★4.3

Editorial score · methodology

$49/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Enhance MD review →

Cost Comparison

Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded naltrexone hydrochloride / bupropion hydrochloride from licensed 503A and 503B pharmacies is legal under federal compounding law[3], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[4]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[5]. Prices may vary based on dose and promo availability.

ProviderStarting Price
Brightmeds$0/moVisit
EverFit Medical$0/moVisit
AM Rx$25/moVisit
Amazon One Medical$25/moVisit
Calibrate Health$25/moVisit
Enhance MD$49/moVisit
Bliv$58/moVisit
Primary Clinic (Direct GLP)$65/moVisit
Boston Medical Group$66/moVisit
Alloy$80/moVisit
Maximus$80/moVisit
Oak$80/moVisit
Ondra Health$93/moVisit
Alan Meds$99/moVisit
Cora Health$99/moVisit
Embody$99/moVisit
Factor Health MD$99/moVisit
Maves (Homera Health)$99/moVisit
AmberHealth$100/moVisit
Care Clinics$100/moVisit
Cielo$115/moVisit
Elara Health and Wellness$117/moVisit
Belle Health$119/moVisit
Ark Health$125/moVisit
Alternate Health Club$129/moVisit
Actin$133/moVisit
BeyondMD$139/moVisit
altRX$149/moVisit
Aquivia Health$149/moVisit
CoreAge Rx$149/moVisit
Curex$149/moVisit
DudeMeds$149/moVisit
Coby Health$159/moVisit
Effecty$160/moVisit
Fella Health$165/moVisit
Elevated Health$176/moVisit
Amble$179/moVisit
Bodybuilding Health+$179/moVisit
Claya$179/moVisit
Eden$189/moVisit
Eve$195/moVisit
AgelessRx$199/moVisit
AMP Health$199/moVisit
BetterMe Rx$199/moVisit
Breeze Meds$199/moVisit
Care Bare Rx$199/moVisit
Concierge MD LA$199/moVisit
AVARA Rx$229/moVisit
Direct Meds$249/moVisit
Arc-1$250/moVisit
Cost Plus Drugs$279/moVisit
Corsica Health$299/moVisit
Emerge Weight Loss$299/moVisit
Fierce Health$NaN/moVisit
Lumen Meds$0/moVisit
FitRx$25/moVisit
LillyDirect Foundayo$25/moVisit
Ivim Health$75/moVisit
Fitish$219/moVisit
FMmeds$NaN/moVisit
Green Cap Health$79/moVisit
Loop Health$79/moVisit
JM Integrated Health$93/moVisit
Lavender Sky Health$95/moVisit
HeliMeds$99/moVisit
Joi + Blokes$99/moVisit
Framework$100/moVisit
GobyMeds$119/moVisit
Found$129/moVisit
Gimme Care$130/moVisit
Fresh Day Meds$133/moVisit
HelloWellness$133/moVisit
LumiMeds$133/moVisit
Ivologist$145/moVisit
Healthicare$148/moVisit
Gala$149/moVisit
GoodRx$149/moVisit
Heva Health$149/moVisit
Kin Meds$149/moVisit
HealthOn$155/moVisit
Injectco$156/moVisit
Get Thin MD$169/moVisit
Ivy Rx$175/moVisit
GetRelief Rx$179/moVisit
GOAL.MD$179/moVisit
HydraMed$179/moVisit
Liv Body$179/moVisit
FuturHealth$199/moVisit
Hers$199/moVisit
Hims$199/moVisit
InstaRX$199/moVisit
Invigor Medical$199/moVisit
Joey Med$199/moVisit
MangoRx$199/moVisit
Levers Health$246/moVisit
Henry Meds$249/moVisit
Independent Wellness$249/moVisit
Livv$249/moVisit
Freya Meds$250/moVisit
Lyfe Rx$289/moVisit
K Health$300/moVisit
Lemonaid Health$348/moVisit
Form Health$1350/moVisit
Medical Health Institute$NaN/moVisit
OrderlyMeds$74/moVisit
Pomegranate Health$90/moVisit
MyFastRx$99/moVisit
Neo Soma Healthcare$99/moVisit
Noom Med$99/moVisit
NewSelf$100/moVisit
Queen RX$100/moVisit
Priority Meds$113/moVisit
Mint Med$117/moVisit
Nova MD$125/moVisit
Midi Health$128/moVisit
Peak Wellness$129/moVisit
PeterMD$135/moVisit
Piper$135/moVisit
Mochi Health$138/moVisit
NexLife$145/moVisit
Nalena$149/moVisit
Obu Health$149/moVisit
PlushCare$149/moVisit
NP2GO$150/moVisit
OnlineSemaglutide.org$150/moVisit
NuvaHealth$159/moVisit
PeptidesRx$169/moVisit
Novi$174/moVisit
MEDVi$179/moVisit
OnlyRx$179/moVisit
Mevo Health$199/moVisit
Mint Medical Clinic$299/moVisit
Mixx Health & Wellness$NaN/moVisit
NativeMed$149/moVisit
Precision Telemed$149/moVisit
Nurx$179/moVisit
ReadyRx$179/moVisit
NiceRx$199/moVisit
NovoCare Pharmacy$199/moVisit
PauseRX$199/moVisit
Navio MD$247/moVisit
MyStart Health$299/moVisit
Mojoon$450/moVisit
myRocky$1409/moVisit
Nouri$NaN/moVisit
WellMedRx$0/moVisit
YOURx Health$0/moVisit
Roen Rx$25/moVisit
Sesame Care$25/moVisit
WeightRx$83/moVisit
Strut Health$99/moVisit
Teleios Health$99/moVisit
Trimi Health$99/moVisit
Vitara RX$99/moVisit
YourEra$99/moVisit
RxPros$99.99/moVisit
Trava Health$119/moVisit
Try Ageless$119/moVisit
Tyde Wellness$119/moVisit
Zeuss$125/moVisit
Regenics$139/moVisit
Velvet Rx$139/moVisit
Yucca Health$146/moVisit
TeleHealth Med$147/moVisit
Ro$149/moVisit
Tonik Wellness$149/moVisit
Vytora Health$150/moVisit
Sunlight$179/moVisit
Vaylen$179/moVisit
WePeptideRx$189/moVisit
Unique Physique$195/moVisit
RNK Health$197/moVisit
Sesame$199/moVisit
ShedRx$199/moVisit
SkinnyRx$199/moVisit
Spry$199/moVisit
Synergy Rx$199/moVisit
TMates$199/moVisit
TOM Weight Loss$199/moVisit
TrimRx$199/moVisit
Wisp$225/moVisit
Remi Meds$249/moVisit
Sprout Health$249/moVisit
WeightCare$249/moVisit
Zealthy$286/moVisit
ReflexMD$297/moVisit
Remedy Meds$299/moVisit
Super Healthy Rx$299/moVisit
Vyora Wellness$299/moVisit
Willow$299/moVisit
Royal Medical Center$450/moVisit
Shape Vantage$599/moVisit
Push Health$950/moVisit
T2D.com$999/moVisit
NowPatient$1069/moVisit

Short-form verdict pages comparing Contrave to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.

See all drug-vs-drug verdicts.

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Does Bupropion Cause Weight Loss? Honest Evidence Review
Bupropion is a norepinephrine and dopamine reuptake inhibitor FDA-approved for depression and smoking cessation, not obesity. As a single agent at 300-400 mg/day it produces -1.5 to -3 kg in routine treatment (5-10% on-trial with diet). Contrave (naltrexone + bupropion) reached…
12 min read8 citations
GLP-1 + Adderall, Vyvanse, or Ritalin: The Stacking Evidence
Stimulants suppress appetite; GLP-1s also suppress appetite. Stacking them creates a compounded caloric-deficit risk and may worsen tachycardia. We review the FDA labels for Adderall, Vyvanse, and Ritalin, plus the bupropion-naltrexone Contrave comparison.
12 min read10 citations
GLP-1 + SSRIs: Lexapro, Zoloft, Prozac Interaction Evidence
About 13% of US adults take an SSRI; many start a GLP-1 alongside. There's no documented PK interaction, but SSRI-related weight effects and serotonin-pathway overlap deserve a closer look. We review STEP/SURMOUNT psychiatric safety + Wadden 2024.
11 min read10 citations
GLP-1 + Wellbutrin (Bupropion): The Stacking Evidence
Wellbutrin (bupropion) is the weight-favorable antidepressant; Contrave already pairs it with naltrexone for weight loss. Stacking with semaglutide or tirzepatide is common but unstudied. We review COR-I, smoking-cessation overlap, and the seizure-threshold ceiling.
11 min read11 citations
Rhode Island Medicaid GLP-1 Coverage 2026: PA Pathway, Eligibility & Appeals
Rhode Island Medicaid CURRENTLY covers Wegovy + Zepbound + Saxenda + Contrave for chronic weight management — one of only 13 states still doing so under FFS Medicaid per KFF January 2026. Governor Daniel McKee's FY2027 Executive Budget Item 028 (EOHHS Rank #2, introduced January.
16 min read17 citations
Why Does Tirzepatide Cause Headaches? (Frequency, Mechanism, and When to Call Your Doctor)
Tirzepatide headache is a listed FDA adverse reaction: Zepbound Section 6.1 reports headache in 11% (5 mg), 12% (10 mg), and 13% (15 mg) vs 9% placebo in SURMOUNT-1 (PMID 35658024). Primary mechanism: dehydration from blunted thirst drive — hypothalamic GLP-1 receptor suppression dampens both hunger and thirst signals. Secondary mechanisms: GI-induced dehydration from nausea/vomiting, blood glucose fluctuations (hypoglycemia in T2D + sulfonylurea — verbatim Zepbound Section 5.7), and caffeine withdrawal from reduced beverage intake. Onset: peaks days 1–7 post-escalation; resolves in 2–4 weeks. Management: 64–80 oz/day active hydration (primary), electrolyte replacement during GI symptoms, acetaminophen preferred over NSAIDs (verbatim Zepbound Section 5.3 kidney-injury warning names NSAIDs as compounding risk), bupropion seizure-risk caveat for Contrave patients. STEP-1 vs SURMOUNT-1 cross-trial headache comparison with mandatory caveat. Emergency flags: thunderclap headache, vision changes, neurological symptoms, fever + stiff neck. DailyMed SetIDs: Zepbound 487cd7e7, Mounjaro d2d7da5d. Verified 2026-05-10.
11 min read5 citations

Frequently Asked Questions

Sources & methodology — as of May 2026
  1. 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDAU.S. Food & Drug Administration.
  2. 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)New England Journal of Medicine.PMID: 33567185.
  3. 3.FDA — Compounding and the 503A Pharmacy FrameworkU.S. Food & Drug Administration.
  4. 4.FDA — Drug Shortages Database (current shortage listings)U.S. Food & Drug Administration.
  5. 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)Internal Revenue Service.